header logo ru2

Understanding clinical trials

Где найти иммуноонкологическое исследование для моего типа рака?

| Печать

Участие в клиническом исследовании может быть хорошим решением, но часто трудно найти клиническое исследование, которое подходит именно вам. В следующей таблице (на английском языке) перечислены некоторые клинические исследования для больных раком почек, которые проводятся в разных странах. В вашей стране могут проводиться другие исследования: О понимании и поиске исследований см. здесь.

Скоро. Пожалуйста, свяжитесь с Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., если вам нужна информация о клинических испытаниях.

 

Pre-surgery (neo adjuvant) trials (for patients before surgery to remove the kidney tumour)

Pre-surgery (neo adjuvant) trials (for patients before surgery to remove the kidney tumour)

 Trial name  Agents  Phase  Status  Sponsor  Further  information
ADAPTeR   Nivolumab pre and post-OP  II           
 Open,
 recruiting
  Royal Marsden  click here
Pembrolizumab-031 Pembrolizumab (MK-3475)  I
 Open,
 recruiting 
 Merck Sharp  
 & Dohme  Corp.
  click here
First line treatment (for patients who have not yet had any systemic therapy for advanced kidney cancer)

First line treatment (for patients who have not yet had any systemic therapy for advanced kidney cancer)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 214   
Nivolumab+ipilimumab  
versus sunitinib
  III  Closed to  accrual Bristol-Myers Squibb  click here
ADAPT
AGS-003 versus
sunitinib
  III  Ongoing,  not  recruiting Argos Therapeutics  click here
Atezolizumab (MPDL3280 A) + bevacizumab versus
sunitinib
  III
 Open,
 recruiting
 Hoffmann-La Roche  click here
Javelin Renal 101 Avelumab + axitinib  III
 Open,
 recruiting
 Pfizer  click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Ongoing,  not  recruiting
 MD Anderson  click here 
Pazopanib +
interferon alpha 2a
  I/II  Completed  Spanish Oncology Genito-Urinary Group
Novartis		  click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
  I/II
 Ongoing,  not  recruiting
 Merck Sharp & Dohme Corp.  click here
Atezolizumab +
interferon alpha 2b
  I
 Ongoing,   not 
 recruiting
 Hoffman-La Roche  click here
Pembrolizumab + pazopanib
Pembrolizumab +
pazopanib
  I  Open,  recruiting
Novartis, 
Merck Sharp
& Dohme Corp.
  click here
Pembrolizumab + axitinb
Pembrolizumab +
axitinb
  I  Ongoing,  not  recruiting Pfizer  click here
Javelin renal 100 Avelumab + axitinib  I
 Ongoing,   not 
 recruiting
 Pfizer  click here

 

Second line treatment (for patients who have had only one prior systemic therapy)

Second line treatment (for patients who have had only one prior systemic therapy)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 025 Nivolumab versus everolimus  III  Stopped,  results  published  at the  ECC  2015 Bristol-Myers Squibb  click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Open,
 recruiting
 MD Anderson  click here 
Pembrolizumab + interferon alpha 2b +
ipilimumab
  I/II  Ongoing,  not  recruiting Merck Sharp & Dohme Corp.  click here
Pazopanib +
interferon alpha 2a
  I/II  Completed  Spanish Oncology Genito-Urinary Group
Novartis		  click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
  I/II
 Open,
 recruiting
 Merck Sharp & Dohme Corp.  click here
Atezolizumab +
interferon alpha 2b
  I
 Ongoing,   not 
 recruiting
 Hoffman-La Roche  click here
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab Cabozantinib + nivolumab + ipilimumab  I
 Open,
 recruiting
 National Cancer Institute (NCI)/ Exelixis  click here
X4P-001 in Patients With Advanced Renal Cell Carcinoma X4P-001 + axitinib  I/II  Open,  recruiting    click here
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360)  Pembrolizumab (MK-3475) + Epacadostat (INCB024360)  I/II  Open  recruiting Incyte Corporation,
Merck Sharp & Dohme Corp.		  click here
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours Lenvatinib + Pembrolizumab   Ib/II  Open  recruiting Eisai Inc.  click here
Third line treatment (for patients who have had up to two prior systemic therapies)

Third line treatment (for patients who have had up to two prior systemic therapies)

 Trial name  Agents  Phase   Status  Sponsor  Further  information 
Checkmate 025 Nivolumab versus everolimus  III  Stopped,  results  published  at the  ECC  2015 Bristol-Myers Squibb  click here
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab  II 
 Open,
 recruiting
 MD Anderson  click here 
Pazopanib +
interferon alpha 2a
  I/II  completed  Spanish Oncology Genito-Urinary Group
Novartis		  click here
Pembrolizumab + bevacizumab
Pembrolizumab +
bevacizumab
  I/II
 Open,
 recruiting
 Merck Sharp & Dohme Corp.  click here
Atezolizumab +
interferon alpha 2b
  I  Ongoing,   not   recruiting Hoffman-La Roche  click here
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab Cabozantinib + nivolumab + ipilimumab  I
 Open,
 recruiting
 National Cancer Institute (NCI)/ Exelixis  click here
X4P-001 in Patients With Advanced Renal Cell Carcinoma X4P-001 + axitinib  I/II  Open,  recruiting    click here
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360)  Pembrolizumab (MK-3475) + epacadostat (INCB024360)  I/II  Open,  recruiting Incyte Corporation,
Merck Sharp & Dohme Corp.		  click here
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours Lenvatinib + Pembrolizumab  Ib/II
 Open,
 recruiting
 Eisai Inc.  click here
Others

Others

Currently no other trials available.